Global Nonalcoholic Steatohepatitis NASH Therapeutics Overview
Introduction:
Non-alcoholic steatohepatitis (NASH) is a type of NAFLD. NASH is the liver damage and inflammation caused by the buildup of fat in the liver. It is part of a group of conditions called non-alcoholic fatty liver disease (NAFLD). Non-alcoholic steatohepatitis (NASH), a destructive form of non-alcoholic fatty liver disease (NAFLD), often progress to more severe disorders, such as hepatocellular carcinoma and cirrhosis. Therefore, it has been estimated that NASH may even surpass the hepatitis C virus infection, becoming the major cause of liver transplantation, worldwide, in the coming decade. However, there are still no FDA-approved therapies for this disorder at present, and there is a need to discover appropriate therapeutic targets. The increasing patient population that lacks available specific treatments creates a huge opportunity for the overall market. Several manufacturers are currently developing drugs for the treatment of NASH, and around 90-100 drugs are in the pipeline, at various stages of development, across the globe.
Drivers and Restraints:
Increase in NASH-affected population globally is the major factor driving growth of the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market. According to the NIH data in 2016, NAFLD was one of the most common causes of liver damage in the U.S. Most cases of NAFLD were observed to be those of simple fatty liver. Only a small number of people, who were suffering from NAFLD, were identified with NASH. Therefore, according to the estimates, about 20% of people, who suffered from NAFLD, were identified with NASH. Additionally, NAFLD is more common in people suffering from certain health conditions, including obesity and related conditions, such as type-2 diabetes. In addition, surge in the prevalence of NASH and launch of pipeline drugs is expected to boost growth of the global market during the forecast period. Moreover, surge in prevalence of diabetes & obesity and improvement in awareness of NASH in developing region is projected to supplement the market growth during the forecast period. However, poor diagnosis of the disease and lack of ideal diagnostic techniques are projected to hamper the target market growth over the forecast period.
Segmentation:
The global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market is segmented based product type and region.
On the basis of product type, the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market is segmented into therapeutics and diagnostics. Therapeutics product type segment is further bifurcated into elafibranor, ocaliva, selonsertib, cenicriviroc, emricasan, and other therapeutics. Elafibranor and selonsertib & cenicriviroc segments are projected to exhibit significant growth over the forecast period, owing to its effectiveness in severely affected NASH patients. Diagnostics product type segment is further classified into imaging techniques, diagnostic tests, and biopsy.
Based on region the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North American market is dominating the target market and is expected maintain its dominace over the forecast period. The prevalence of non-alcoholic fatty liver disease is due to the rising trend of obesity in the region. Non-alcoholic fatty liver disease (steatohepatitis) is considered as the most common form of chronic liver disease. According to data published by the Intermountain Healthcare researchers, on the economic impact of the disease, each year approximately 100 million Americans are affected by the non-alcoholic fatty liver disease. The cost of the disease impacting the U.S. healthcare system is nearly US$ 32 billion, annually. Asia-Pacific offers numerous opportunities for the key players operating in the global non-alcoholic steatohepatitis (NASH) market. Some factors such as rapid rise in prevalence NASH, growth in diagnostic techniques, growth in economies, and increase in demand for NASH therapeutics boost the market growth in Asia-Pacific. Some other factors such as emerging economies, developing healthcare infrastructure, and growing rate of diagnosis are further projected to drive growth of the non-alcoholic steatohepatitis (NASH) market in Asia-Pacific. Moreover, rising healthcare awareness in the emerging economies such as India and China further fuel the growth of the target market.
Key Players:
The key players operating the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market involves Novartis AG, Allergan PLC, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Intercept Pharmaceuticals Inc., Gilead Sciences Inc., Novo Nordisk A/S, Zydus Cadila, Genfit SA, and Merck & Co. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market. For instance, in February 2019, Intercept Pharmaceuticals Inc. stated positive results from its pivotal Phase 3 REGENERATE study of obeticholic acid (OCA), in patients with liver fibrosis, due to nonalcoholic steatohepatitis (NASH).
Detailed Segmentation:
Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Product:
- Therapeutics
- Elafibranor
- Ocaliva
- Selonsertib
- Cenicriviroc
- Emricasan
- Other Therapeutics
- Diagnostics
- Imaging Techniques
- Diagnostic Tests
- Biopsy
Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Region:
-
-
- North America
- North America Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Product
- North America Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Country
- U.S.
- Canada
- Europe
- Europe Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Product
- Europe Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Country
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Asia Pacific Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Product
- Asia Pacific Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Country
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Latin America Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Product
- Latin America Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Country
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Product
- Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Country
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- North America
-
Company Profile:
-
-
- Novartis AG *
- Company Overview
- Novartis AG *
-
-
-
-
- Product Portfolio
- Key Highlights
- Financial Performance
-
-
- Allergan PLC
- Madrigal Pharmaceuticals
- Galmed Pharmaceuticals
- Intercept Pharmaceuticals Inc.
- Gilead Sciences Inc.
- Novo Nordisk A/S
- Zydus Cadila
- Genfit SA
- Merck & Co.
“*” marked represents similar segmentation in other categories in the respective section
Key Issues Addressed
- What is the total revenue potential of the global the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market?
- How that market is expected to grow during the study period?
- What are some of the major growth opportunities in the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market?
- Which companies are the major players in the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market?
FAQs
The non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market is segmented based product type and region.
the development of novel therapeutics, the focus on non-invasive diagnostics, and advancements in understanding NASH pathophysiology, presenting significant opportunities in the global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market.
increasing prevalence of NASH, the rising awareness of liver diseases, advancements in diagnostic imaging and biomarker technologies, and the urgent need for effective NASH therapeutics.
North America and Europe are expected to dominate the Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, driven by a high prevalence of NASH, advanced healthcare infrastructure, and significant research and development activities in these regions.
The key players operating the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market involves Novartis AG, Allergan PLC, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Intercept Pharmaceuticals Inc., Gilead Sciences Inc., Novo Nordisk A/S, Zydus Cadila, Genfit SA, and Merck & Co.